Madrigal Pharmaceuticals, Inc. (BIT:1MDGL)
499.20
-5.60 (-1.11%)
At close: Dec 4, 2025
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $287.27M USD in the quarter ending September 30, 2025, with 362.03% growth. This brings the company's revenue in the last twelve months to $740.64M, up 864.21% year-over-year. In the year 2024, Madrigal Pharmaceuticals had annual revenue of $180.13M.
Revenue (ttm)
$740.64M
Revenue Growth
+864.21%
P/S Ratio
17.85
Revenue / Employee
$1.40M
Employees
528
Market Cap
11.27B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 180.13M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Stellantis | 146.12B |
| Eni S.p.A. | 86.56B |
| Enel SpA | 77.78B |
| Assicurazioni Generali | 56.79B |
| Intesa Sanpaolo | 25.32B |
| UniCredit | 24.85B |
| Prysmian | 19.49B |
| Leonardo S.p.a. | 19.13B |